13
Participants
Start Date
September 23, 2020
Primary Completion Date
February 9, 2022
Study Completion Date
May 28, 2025
Ibrutinib
Capsule; Oral
Venetoclax
Tablet; Oral
Tohoku University Hospital /ID# 221975, Sendai
NHO Nagoya Medical Center /ID# 221958, Nagoya
Aichi Cancer Center Hospital /ID# 221565, Nagoya
Kyushu University Hospital /ID# 223299, Fukuoka
Hokkaido University Hospital /ID# 221662, Sapporo
Kobe City Medical Center General Hospital /ID# 221744, Kobe
National Hospital Organization Mito Medical Center /ID# 224912, Higashi Ibaraki-gun
Ishikawa Prefectural Central Hospital /ID# 224896, Kanazawa
Duplicate_Okayama University Hospital /ID# 221623, Okayama
Saitama Medical Center /ID# 224910, Kawagoe-shi
National Cancer Center Hospital /ID# 221812, Chuo-ku
Yamagata University Hospital /ID# 221573, Yamagata
Lead Sponsor
AbbVie
INDUSTRY